Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

	Equivalent of Form PTO/SB/08a (07-09				
Complete if Known					
Application Number	10/550,196				
Filing Date	January 12, 2007				
First Named Inventor	Madeleine M. Joullie				
Art Unit	1654				
Examiner Name	CORDERO GARCIA, MARCELA M.				
Attorney Docket Number	1694.0610001/JMC/THN				

			U.S. PATEN	IT DOCUMENTS	
Examiner initials*	Cite	Document Number Number-Kind Code ^{2 (if}	Publication Date	Name of Patentee or Applicant of Citied Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures
initials"	No. ¹	known)			Appear
	US7	4,493,796	01-15-1985	Rinehart, Jr.	
	US8	4,782,135	11-01-1988	Rinehart, Jr.	
	US9	5,137,870	08-11-1992	Rinehart	
	US10	5,504,189	04-02-1996	Emling et al.	
	US11	7,064,105 B2	06-20-2006	Joullié <i>et al</i> .	
	US12	7,122,519 B2	10-17-2006	Joullié et al.	
	US13	2003/0104991 A1	06-05-2003	Joullie et al.	
	US14	2007/0129289 A1	06-07-2007	Joullie et al.	

Examiner initials*		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	Cite No.1	Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Citied Document	Where Relevant Passages or Relevant Figures Appear	Т6
	FP2	ES 2 102 322 A1	07-16-1997	Pharma Mar, S.A.		
, .	FP3	WO 98/17302 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP4	WO 98/17302 A1 (Corrected Version)	04-30-1998	The Board of Trustees of the University of Illinois		
	FP5	WO 98/17275 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP6	WO 02/02596 A2	01-10-2002	Pharma Mar, S.A.		

1125118 1.DOC

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for for	NFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known					
				Application Number	10/550,196		
FIRST SUPPLEMENTAL			ΓAL	Filing Date	January 12, 2007		
INFORMA	NFORMATION DISCLOSURE			First Named Inventor	Madeleine M. Joullie		
STATEME	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		PLICANT	Art Unit	1654		
			Examiner Name	CORDERO GARCIA, MARCELA			
				LXammer Name	M.		
Sheet	1	of	4	Attorney Docket Number	1694.0610001/JMC/THN		

Examiner	Cite No.	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Initials*	Cite No.	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
	NPL48	Abdel-Magid, A.F, <i>et al.</i> , "Reductive Amination of Aldehydes and Ketones by Using Sodium Tricetoxyborohydride," <i>Tetrahedron Lett. 31</i> :5595-5598, Pergamon Press plc, UK (1990)	
	NPL49	Abdel-Magid, A.F. & Maryanoff, C.A, "Reductive Amination of Aldehydes and Ketones with Weakly Basic Anilines Using Sodium Triacetoxyborohydride," <i>Synlett.</i> 537-539, Germany (1990)	
	NPL50	Ahuja, D., et al., "Inhibition of Protein Synthesis by Didemnin B: How EF-1α Mediates Inhibition of Translocation," <i>Biochemistry</i> 39:4339-4346, American Chemical Society, United States (2000)	
	NPL51	Ahuja, D., et al., "Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR," J. Med. Chem. 43:4212-4218, American Chemical Society, United States (2000)	
	NPL52	Campbell, MJ., <i>et al.</i> , "Growth inhibition of DU-145 prostate cancer cells by a <i>Bcl-2</i> antisense oligonucleotide is enhanced by <i>N</i> -(2-hydroxyphenyl.)all- <i>trans</i> retinamide," <i>Brit. J. of Cancer 77</i> :739-744, Cancer Research Campaign, UK (1998)	
	NPL53	Crews, C.M., <i>et al.</i> , "Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis," <i>Proc. Natl. Acad. Sci. USA 93</i> :4316-4319, Natl. Acad. Sci., United States (1996)	
	NPL54	Ding, X., et al., "Structure-Activity Relationships of Side-Chain Modified Didemnins," Bioorg. Med. Chem. Lett. 11:231-234, Elsevier Science Ltd., United States (2001)	
	NPL55	Ewing, W.R., et al., "SYNTHETIC STUDIES OF DIDEMNINS. 1. REVISION OF THE STEREOCHEMISTRY OF THE HYDROXYISOVALERYLPROPIONYL (HIP) UNIT.," Tetrahedron 42:5863-5868, Pergamon Journals Ltd., UK (1986)	
	NPL56	Ewing, W.R., et al., "SYNTHETIC STUDIES OF DIDEMNINS. IV. SYNTHESIS OF THE MACROCYCLE," <i>Tetrahedron Lett.</i> 30:3757-3760, Maxwell Pergamon Macmillan plc, UK (1989)	
	NPL57	Harris, B.D., et al., "SYNTHETIC STUDIES OF DIDEMNINS. II. APPROACHES TO STATINE DIASTEREOMERS," <i>Tetrahedron Lett.</i> 28:2837-2840, Pergamon Journals Ltd., UK (1987)	

Examiner Da	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Applicant is a strategic to the complete desprication form to the USPTO. Time will vary depending upon the individual case. Application for requiring this form and/or suggestions for requiring this burden, should be sent to the Chief Information. including gathering, preparing, and submitting the completed application for the OSFTO. Three will vary depending upon the included case. Why comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO	Complete if Known			
	Application Number	10/550,196		
FIRST SUPPLEMENTAL	Filing Date	January 12, 2007		
INFORMATION DISCLOSURE	First Named Inventor	Madeleine M. Joullie		
STATEMENT BY APPLICANT	Art Unit	1654		
(Use as many sheets as necessary)	Examiner Name	CORDERO GARCIA, MARCELA		
·	Examiner Name	M.		
Sheet 2 of 4	Attorney Docket Number	1694.0610001/JMC/THN		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	Т
	NPL58	Harris, B.D., et al., "SYNTHETIC STUDIES OF DIDEMNINS. III: SYNTHESES OF STATINE AND ISOSTATINE STEREOISOMERS," <i>Tetrahedron 44</i> :3489-3500, Pergamon Press plc, UK (1988)	
	NPL59	Jou, G., et al., "Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution," <i>J. Org. Chem.</i> 62:354-366, American Chemical Society, United States (1997)	
	NPL60	Joullié, M.M., <i>et al.</i> , "Total Synthesis of (-)-tamandarin B," <i>Tetrahedron Lett. 41</i> :9373-9376, Elsevier Science Ltd., UK (2000)	
	NPL61	Joullié, M.M., et al., "Chemical Defense in Ascidians of the Didemnidae Family," Bioconjugate Chem. 14:30-37, American Chemical Society, United States (2003)	
	NPL62	Li, WR. & Joullié, M.M., "The Didemnins: Biological Properties, Chemistry and Total Synthesis," <i>Studies in Natural Products Chemistry</i> , <i>10</i> :241-302, Elsevier Science Publishers B.V., The Netherlands (1992)	
	NPL63	Mayer, S.C., et al., "Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships," J. Org. Chem., 59:5192-5205, American Chemical Society, United States (1994)	
	NPL64	Mayer, S.C., et al., "Synthetic Routes to a Constrained Ring Analog of Didemnin B," J. Org. Chem. 61:1655-1664, American Chemical Society, United States (1996)	
	NPL65	Mayer, S.C., et al., "Synthetic Studies of a Constrained Ring Didemnin Analog," Tetrahedron: Asymmetry 5:519-522, Elsevier Science Ltd., UK (1994)	
	NPL66	Mayer, S.C., et al., "The Cyclic Depsipeptide Backbone of the Didemnins," Acta. Cryst. C51:1609-1614, International Union of Crystallography, UK (1995)	
	NPL67	Pfizenmayer, A.J., et al., "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF [N-MeLeu ⁵) DIDEMNIN B," Biog. Med. Chem. Lett. 6:2713-2716, Elsevier Science Ltd., UK (1996)	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form	1449/PT	0		Con	nplete if Known
				Application Number	10/550,196
FIRST SUP	PLEN	/IEN	ΓAL	Filing Date	January 12, 2007
INFORMATION DISCLOSURE		LOSURE	First Named Inventor	Madeleine M. Joullie	
STATEMEN	NFORMATION DISCLOSURE	PLICANT	Art Unit	1654	
	Examiner Name	CORDERO GARCIA, MARCELA			
				Examiner Name	M.
Sheet	3	of	4	Attorney Docket Number	1694.0610001/JMC/THN

Examiner Initials*	Cite No.	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T^2
	NPL68	Portonovo, P., et al., "First Total Synthesis of a Fluorescent Didemnin," <i>Tetrahedron</i> 56:3687-3690, Elsevier Science Ltd., UK (2000)	
	NPL69	Ramanjulu, J.M., <i>et al.</i> , "A Facile Synthesis of Benzyl 2-Amino-3-Azido-4- <i>O-p</i> -Methoxybenzyl-6- <i>O</i> -Benzyl-2,3-Dideoxy-α-D-Glucopyranoside: A Key Intermediate in the Formation of a Didemnin B Analog," <i>J. Carbohydrate Chemistry</i> 15:371-381, Marcel Dekker, Inc., United States (1996)	
	NPL70	Ramanjulu, J.M., et al., "Analogs of the β-Turn of the Cyclodepsipeptide Didemnin B," Tetrahedron Letters 37:311-314, Elsevier Science Ltd., UK (1996)	
	NPL71	Ramanjulu, J.M., et al., "Syntheses of Acyclic Analogs of Didemnin B," Synthetic Communications 27:3259-3272, Marcel Dekker, Inc., United States (1997)	
	NPL72	Ramanjulu, J.M., et al., "Synthesis of a Reduced Ring Analog of Didemnin B," J. Org. Chem. 62:4961-4969, American Chemical Society, United States (1997)	
	NPL73	Ramanjulu, J.M., et al., "Synthetic Studies of a Didemnin B Analog Based on a 2,3-Diamino Sugar Scaffolding," J. Chin. Chem. Soc. 48:1-4, The Chemical Society, Taiwan (2001)	
	NPL74	Schumacher, K.K., <i>et al.</i> , "Synthetic studies toward astins A, B and C. Efficient syntheses of <i>cis</i> -3,4-dihydroxyprolines and (-)-(3 <i>S</i> ,4 <i>R</i>)-dichloroproline esters," <i>Tetrahedron: Asymmetry</i> 9:47-53, Elsevier Science Ltd., UK (1998)	
	NPL75	Tarver Jr., J.E., <i>et al.</i> , "Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements of <i>N</i> , <i>O</i> -Dimethyltyrosine with L-1,2,3,4-Tetrahydroisoquinoline and L-1,2,3,4-Tetrahydro-7-methoxyisoquinoline," <i>J. Org. Chem.</i> 66:7575-7587, American Chemical Society, United States (2001)	
and the state of t	NPL76	Vera, M.D., et al., "[Lys³] Didemnins as Potential Affinity Ligands," Biorg. Med. Chem. Lett. 11:13-16, Elsevier Science Ltd., UK (2001)	
	NPL77	Vera, M.D. & Joullié, M.M., "Natural Products as Probes of Cell Biology: 20 Years of Didemnin Research," <i>Medicinal Research Reviews 22</i> :102-145, John Wiley & Sons, Inc., United States (2002)	

Ī	Examiner	Date	
	Signature	Considered	
1			<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/550,196	
FIRST SUP	PLEN	IEN	ΓAL	Filing Date	January 12, 2007	
INFORMAT	ION D	ISC	LOSURE	First Named Inventor	Madeleine M. Joullie	
STATEMEN	NT BY	API	PLICANT	Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	CORDERO GARCIA, MARCELA M.	
Sheet	4	of	4	Attorney Docket Number	1694.0610001/JMC/THN	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	NPL78	Vera, M.D., et al., "Synthesis and Biological Evaluation of Didemnin Photoaffinity Analogues," Biorg. Med. Chem. Lett. 11:1871-1874, Elsevier Science Ltd., UK (2001)		
	NPL79	Vervoort, H. & Fenical, W., "Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae," <i>J. Org. Chem.</i> 65:782-792, American Chemical Society, United States (2000)		
	NPL80	Wipf, P., "Synthetic Studies of Biologically Active Marine Cyclopeptides," <i>Chem. Rev.</i> 95:2115-2134, American Chemical Society, United States (1995)		
	NPL81	Xiao, D., et al., "Total Synthesis of a Conformationally Constrained Didemnin B," <i>J. Org. Chem.</i> 66:2734-2742, American Chemical Society, United States (2001)		
	NPL82	STNEasy/CAplus English language Abstract of Spanish Patent Publication No. ES 2 102 322 A1 (1997), document FP1, Accession No. 1998:169709		
1.13(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(

1125067_1.DOC

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line inrough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.